Drug Delivery Technology for Posterior Eye Segment

Request Number REQ6356781
Due Date November 30, 2017
Request for Proposal Details
RFP Title
Drug Delivery Technology for Posterior Eye Segment
RFP Description

NineSigma, representing a leading pharmaceutical company, seeks drug delivery technologies for the posterior eye segment.


Today, owing to the aging society and development of lifestyle diseases, diseases in the posterior eye segment are increasing, such as age-related macular degeneration and diabetic retinopathy. However, delivering drugs to the posterior eye segment is difficult because of the defense mechanism of ocular tissues, and challenges include low efficiency of delivery to the target sites and short duration of drug efficacy. In addition, treatment with injection involves severe pain and side effects; invasive methods of administration are another problem.


The client is widely recruiting drug delivery technologies for the posterior eye segment to solve these challenges, regardless of the modality and method of administration. 

Key Success Criteria

Requirements for the Drug Delivery Technologies

  • Modalities to which the technology will be applied: low molecular compounds, peptides, proteins, nucleic acids, cells, etc.

Should meet target performance for methods of administration listed below: 

  • Administration without Injection
    • Technologies with high delivery efficiency to the retina (desirably, 0.1% or more of administered drug, or 10-fold or more increase compared to the control, should be delivered to the retina).
  • Administration by Injection
    • Technologies to deliver drug to the targeted site on the retina
    • Technologies to extend period for controlled release or duration of drug efficacy in vivo (desirably, more than 3 months compared to the control)
    • Less invasive administration (desirably, less than or equal to intravitreal injection)
    • If using nucleic acids or genes, non-viral vector technologies (desirably, with an expression rate at least 100-fold higher than the control)
    • If using cells, technologies to improve taking rate
    • Technologies with biodegradability or removability
    • Desirably, with in vivo data 

Possible Approaches

Examples might include, but are not limited to:

  • Administration without Injection
    • Technologies to promote corneal penetration
      • Particulate eye drops
      • Device to promote penetration
  • Administration by Injection
    • Technologies for intraocular controlled release
      • Particulates for controlled release
      • Rod-shaped implants
    • Gene Delivery Technologies
      • Electroporation
    • Cell Delivery Technologies
    • Injectable Gel

Approaches not of interest

The following approaches are not of interest:

  • Technologies unlikely to have biocompatibility 
  • Technologies unlikely to be produced on a large scale and aseptically in the future 


Anticipated Project Phases or Project Plan

Respondents should submit proposals using the attached Response Template.

The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities.

The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

Preferred Collaboration types
  • Joint Development
  • Technology Licensing
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments“ shown at the bottom of the link <REQ6356781> and include the following items:


  • Summary of drug delivery technology proposed (such as modality, method of administration, uniqueness)
  • Present performance
    • Modality to which the technology will be applied
    • Methods for administration
    • Data showing drug delivery efficiency and improved drug efficacy (desirably in vivo)
    • Duration for controlled release and drug efficacy in vivo
    • Results of safety studies
    • Data showing biodegradability or can be removed from administration site
  • Current research & development stage 
  • Research and development plan
  • Request for form of collaboration
  • Status of intellectual properties for the technology proposed
  • Research performance

Area of Interest
Request Priority